Transposagen, CDI enter license agreement for iPS cell line production

Transposagen Biopharmaceuticals, Inc. (Transposagen), a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International (CDI), the world's largest producer of human induced pluripotent stem (iPS) cell lines and tissue cells for drug discovery and safety.

The license agreement allows CDI to use Transposagen's piggyBac technology in the creation of its products. The piggyBac technology is a highly versatile non-viral method for genetic engineering and stable transgene expression. "We are pleased to be partnering with CDI," said Dr. Eric Ostertag, President and CEO of Transposagen. "Like Transposagen, their products are revolutionizing the drug discovery process."

"CDI is committed to providing human cells derived from iPS cells in the quality, purity, and quantity required by customers, enabling them to concentrate on generating reliable, reproducible, and predictive data and not on creating the cells themselves," said Bob Palay, CDI CEO and chairman of the board. "Toward that end, CDI continues to seek and license in useful technologies, such as piggyBac, that may help improve our manufacturing capabilities." In addition to its iCell™ Cardiomyocytes product line, CDI is planning to launch hepatocytes, neurons, and endothelial cells in the next year.  

The two companies have also agreed to a research and development collaboration.  Transposagen was granted a research license to any cell or product developed by CDI that uses piggyBac for its creation.  Transposagen, the worldwide leader in genetically modified rats, may use CDI's cells to develop "humanized rats," rats that contain organs predominantly consisting of human-derived cells.  Transposagen is developing products expected to improve drug discovery and development by more accurately predicting human response to potential therapeutics at the pre-clinical stage.